Literature DB >> 10540008

Clinical characteristics of SOD1 gene mutations in UK families with ALS.

R W Orrell1, J J Habgood, A Malaspina, J Mitchell, J Greenwood, R J Lane, J S deBelleroche.   

Abstract

Five to ten percent of patients with ALS have a family history of the disease, inheritance is usually autosomal dominant. Mutations of the SOD1 gene were first identified in a proportion of families with ALS by Rosen et al. The SOD1 gene encodes the enzyme copper zinc superoxide dismutase. Patients were studied from throughout the UK, where more than one individual in the family had ALS. Clinical history and examination of the individual and family were obtained, and DNA extracted from leukocytes of whole blood samples. Mutations were identified by standard sequencing methods. To date, 12 different mutations of SOD1 have been identified in 17 different families, representing around 20% of all ALS families studied. The mutations were mainly single base substitutions - H48Q, G72S, G93R, G93V, E100G, D101N, D101G, G108V, I113T, D125H, I149T - and also an insertion mutation - 132insTT - leading to a premature stop codon. The mutations were present in exons 2-5. We did not identify mutations in exon 1, although these have been identified by others in different patient samples. We have identified SOD1 mutations in around 20% of UK families with ALS studied. This is similar to that reported in other populations. Mutations have now been identified in all exons of SOD1. The individual mutations do not precisely predict disease severity, and generally it is difficult to give a specific prognosis based on the individuals' SOD1 mutations. We continue to investigate the possible pathogenic mechanisms of the SOD1 mutations. We have studied the neuropathology in patients with SOD1 mutations. We are also performing linkage studies to identify the genes involved in the 80% of families where an SOD1 mutation has not been identified.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10540008     DOI: 10.1016/s0022-510x(99)00216-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  11 in total

1.  How does the genetic assassin select its neuronal target?

Authors:  James C Stevens; Elizabeth M C Fisher; Simon Mead
Journal:  Mamm Genome       Date:  2011-03-04       Impact factor: 2.957

Review 2.  Inflammatory mediators as biomarkers in brain disorders.

Authors:  Domenico Nuzzo; Pasquale Picone; Luca Caruana; Sonya Vasto; Annalisa Barera; Calogero Caruso; Marta Di Carlo
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

3.  Nanopore Fabrication and Application as Biosensors in Neurodegenerative Diseases.

Authors:  Brian Lenhart; Xiaojun Wei; Zehui Zhang; Xiaoqin Wang; Qian Wang; Chang Liu
Journal:  Crit Rev Biomed Eng       Date:  2020

4.  Tollgate-based progression pathways of ALS patients.

Authors:  Özden O Dalgıç; F Safa Erenay; Kalyan S Pasupathy; Osman Y Özaltın; Brian A Crum; Mustafa Y Sir
Journal:  J Neurol       Date:  2019-01-25       Impact factor: 4.849

Review 5.  U7 snRNA: A tool for gene therapy.

Authors:  Ankur Gadgil; Katarzyna Dorota Raczyńska
Journal:  J Gene Med       Date:  2021-02-23       Impact factor: 4.565

Review 6.  The Role of immune and inflammatory mechanisms in ALS.

Authors:  P A McCombe; R D Henderson
Journal:  Curr Mol Med       Date:  2011-04       Impact factor: 2.222

7.  Targeted Genetic Screen in Amyotrophic Lateral Sclerosis Reveals Novel Genetic Variants with Synergistic Effect on Clinical Phenotype.

Authors:  Johnathan Cooper-Knock; Henry Robins; Isabell Niedermoser; Matthew Wyles; Paul R Heath; Adrian Higginbottom; Theresa Walsh; Mbombe Kazoka; Paul G Ince; Guillaume M Hautbergue; Christopher J McDermott; Janine Kirby; Pamela J Shaw
Journal:  Front Mol Neurosci       Date:  2017-11-09       Impact factor: 5.639

8.  Temporal evolution of the microbiome, immune system and epigenome with disease progression in ALS mice.

Authors:  Claudia Figueroa-Romero; Kai Guo; Benjamin J Murdock; Ximena Paez-Colasante; Christine M Bassis; Kristen A Mikhail; Kristen D Raue; Matthew C Evans; Ghislaine F Taubman; Andrew J McDermott; Phillipe D O'Brien; Masha G Savelieff; Junguk Hur; Eva L Feldman
Journal:  Dis Model Mech       Date:  2019-11-15       Impact factor: 5.758

9.  Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival.

Authors:  Qi Wang; Joshua L Johnson; Nathalie Y R Agar; Jeffrey N Agar
Journal:  PLoS Biol       Date:  2008-07-29       Impact factor: 8.029

Review 10.  The NRF2-Dependent Transcriptional Regulation of Antioxidant Defense Pathways: Relevance for Cell Type-Specific Vulnerability to Neurodegeneration and Therapeutic Intervention.

Authors:  Stephanie M Boas; Kathlene L Joyce; Rita M Cowell
Journal:  Antioxidants (Basel)       Date:  2021-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.